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Background: Antibiotic therapy is thought to improve lung function in patients with cystic fibrosis (CF) by decreasing neutrophil-derived
inflammation. We investigated the origin and clinical significance of lactate in the chronically inflamed CF lung.
Methods: Lactate was measured in sputa of 18 exacerbated and 25 stable CF patients via spectrophotometry and gaschromatography. Lung
function was assessed via spirometry. Seven patients with chronic obstructive pulmonary disease (COPD) and three patients with acute lung
inflammation served as control groups. Neutrophil and bacterial lactate production was assessed under aerobic and anaerobic conditions.
Results: In sputum specimens of patients with respiratory exacerbations lactate concentrations decreased significantly (pb0.005) from 3.4±2.3 mmol/L to
1.4±1.4 mmol/L after 2–3 weeks of intravenous antibiotics. Successful treatment was reflected in 16 patients (88.9%) by FVC increase associated with
lactate decrease (pb0.05). In every single sputum lactate was detectable (3.0±3.1 mmol/L, range 0.2–14.1 mmol/L). Lactate was lower (1.6±0.8 mmol/L)
in sputa from seven COPD patients, and it was below the detection limit in three patients with acute lung inflammation. Neutrophil lactate production
accumulated up to 10.5 mmol/L after 4 days, whereas bacterial lactate production did not appear to contribute substantially to sputum lactate concentrations.
Conclusions: Successful antibiotic therapy is reflected by a decrease in lactate concentrations. Neutrophils are the most likely source for lactate in
sputum of CF patients. Therefore lactate may be used to monitor responses to antibiotic therapy as an adjunct to lung function measurements.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Exacerbations; Neutrophil granulocytes1. Introduction
Cystic fibrosis (CF) is the most common severe autosomal
recessive disease in Caucasians [1,2]. The disease is caused by a
defect in a 230 kb gene on chromosome 7 encoding for the CFTR⁎ Corresponding author. Institute of Hygiene, University Hospital Halle-
Wittenberg, Magdeburger Str. 24, 06112 Halle/Saale, Germany. Tel.: +49 345
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doi:10.1016/j.jcf.2010.09.004protein, which functions as a chloride channel in epithelial cells
[3–5]. Secondary chronic microbial lung infections combined
with progressively worsening lung inflammation are the major
cause for the limited life expectancy of CF patients [1,2,6,7].
Chronic lung inflammation is present early after birth [8,9].
Inflammation causes cumulative epithelial cell damage, loss of
alveoli, and enventual replacement and obliteration of alveoli and
epithelium by connective tissue [10,11].
Defective mucociliary clearance and plugging of airways
with predominantly anaerobic mucus are perceived as majord by Elsevier B.V. All rights reserved.
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patients [12]. Mucus plaques have been shown to become
colonized by a variety of facultative anaerobic bacteria as well
as by many obligate anaerobes [13–15]. Pseudomonas
aeruginosa and Staphylococcus aureus produce exopolysac-
charides such as alginate or poly-N-succinyl glucosamine
during growth under anaerobic conditions which promote the
formation of bacterial microcolonies that cannot be eradicated
by neutrophils [12,16,17] However, neutrophils that are
sequestered in large numbers in the airways release proteolytic
enzymes such as elastase and cathepsin G that contribute to
epithelial injury, tissue remodeling, and destruction of lung
airway walls and alveoli [11,18,19].
CF lung disease is usually treated with chronic antibiotics,
but acute exacerbations occur frequently in many patients and
accelerate the tempo of lung function decline due to intensified
inflammation and lung damage [20,21]. Exacerbations require
even more intensive antibiotic therapy, administered by the
intravenous and inhalation route [6,21]. Although spirometric
determinations of lung function are currently used to assess the
efficacy of antibiotic treatment during acute exacerbations,
other markers may provide additional diagnostic value.
Lactate is a metabolite which may be produced by bacteria
and by human cells as well aerobically as during anaerobic
glukolysis [22–24]. Thus, we investigated lactate concentra-
tions in CF sputum before and after antibiotic treatment of acute
exacerbations. In addition, we measured lactate in sputum from
stable CF patients and correlated lactate levels with lung
function parameters. Lactate concentrations in sputa of COPD
patients, and in bronchoalveolar lavage (BAL) from CF patients
and from patients without sputum production were investigated
for control purposes. The aerobic and anaerobic lactate
production of human neutrophils and of facultative and obligate
anaerobic bacteria was quantified in vitro. Taken together, our
data suggest that lactate levels may be useful to guide antibiotic
therapy when used as an adjunct to lung function measurements
in CF patients with exacerbations of chronic lung infections.2. Methods
2.1. Patients
18 CF patients with exacerbations (six patients from the
University Hospital Halle, Germany, and twelve attending the
Cystic Fibrosis Centre at the University of Florence, Italy; age
26.3±10.7 years, range 7 to 44 years) were included in the
study. Lung function values increased insignificantly from
41.7±18.4% age predicted (range: 23.2 to 79.1%) for FEV1 and
60.3±21.0% (range: 39.9 to 106.8%) for FVC before to
52.0±19.8% (range: 20.3 to 99.6%) for FEV1 and 70.7±19.9
(range: 37.3 to 116.3%) for FVC after treatment. Exacerbations
were defined according to Fuchs [20]. Sputum samples were
taken before and after the antibiotic treatment. Treatment was
performed for two or three weeks i.v. courses with meropenem,
piperacillin/tazobactam, or ceftazidime, selected according to
the resistence pattern of the respective bacteria.Another 25 CF patients without exacerbations (age
28.0±9.6 years, range 18 to 63 years) attending the University
Hospital Halle participated in the study. Values for FEV1
ranged from 18.0 to 100.1% age predicted (57.8±23.0%), FVC
from 43.0 to 104.9% (76.6±19.7%). 14 patients chronically
were infected with P. aeruginosa, 10 harboured S. aureus, and
one patient Burkholderia cenocepacia. All patients received
inhaled tobramycin and/or colistin plus oral azithromycin.
Diagnosis of CF was confirmed by sweat testing and/or
genotyping. All patients had to be able to expectorate sputum.
Samples were vortexed vigorously, and centrifuged (4.000 g for
10 min). Lung function parameters were collected using
bodyplethysmography (MasterScreen Body, Jaeger, Germany)
or a portable spirometer (ZAN 100, morgan strumenti
scientifici, Italy). All patients gave their written informed
consent. The research was carried out in accordance with the
Helsinki Declaration and approved by the local ethics
committees.
In seven CF patients (5 males, 2 females, mean age
23.0±6.1 years, range 17–35 years, FEV1 47.1±14.3% pre-
dicted) from the Adult Cystic Fibrosis Clinic, Madison, WI, U.
S.A., BAL was performed as described previously [10]. Lactate
in BAL was measured before and after treatment of exacerba-
tions. Neutrophils were counted using hemocytometer and
cytocentrifuge preparations stained with Diff-Quick (Baxter,
Miami, FL, U.S.A.).
For control purposes, sputa of seven stable male patients
from the University Hospital Halle with COPD (age
68.6±6.6 years, FEV1 72.9±12.5%, FVC 77.9±12.8%) were
investigated for their lactate content. In BAL of three patients
from Halle without sputum production (I: hepatitis B with renal
insufficiency and pleurorrhoea, 50 years; II: exclusion of
sarcoidosis, 56 years; and III: collapse resulting in serial rib
fractures and pneumothorax, 52 years) lactate was determined.
2.2. Lactate measurement
Measurement of L-lactate was performed spectrophotomet-
rically using an automated test system (Synchron LX, Beckman
Coulter, Fullerton, CA, U.S.A.). In this assay, lactate oxidase
converts lactate to pyruvate with the concomitant generation of
H2O2 which forms a chromophore and is determined by
measuring the absorbance at 520 nm. For quantification of
bacterial D-lactate production, in all sputum samples and all in
vitro-experiments the total lactate production (L-lactate plus D-
lactate) was measured gaschromatographically (Shimadzu-GC
14A, Columbia, MD, USA). Detection limit for both methods:
0.2 mmol/L.
2.3. LDH and MPO measurement
In 29 CF sputum samples, lactate dehydrogenase (LDH) was
determined using the automated Synchron CX system (Beck-
man Coulter). The absorbance at 340 nm is directly proportional
to the LDH activity given in μmol/L s with 1 μmol/L s
equivalent to 60 IU/L. For determination of the influence of
storing conditions on the stability of lactate and LDH
Fig. 1. Individual (•) and mean (■) lactate concentrations in sputum of 18 CF
patients before (pre) and after (post) i.v. antibiotic treatment because of
exacerbations decrease significantly (A, p=0.0043), whereas FVC simulta-
neously increases (B, p=0.13).
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frozen at −51 °C or stored at 6 °C. At day 1 and day 30 lactate
concentrations and LDH activities were measured. MPO
activities in sputum supernatants were determined photometri-
cally at 470 nm, following the MPO catalyzed oxidation of
guaiacol to tetraguaiacol by H2O2.
2.4. Neutrophil lactate production
Neutrophils were purified from heparinized buffy coats from
the blood donation service in Halle, and samples were subjected
to cell separation using biocoll isotonic solution (Biochrom AG,
Berlin, Germany). Neutrophil aliquots [5×106 neutrophils/ml]
were incubated at 37 °C aerobically and anaerobically for 4 h.
Half of each preparation was frozen at −20 °C for an additional
2 h for cell membrane disruption. In independent experiments,
neutrophils were isolated from blood of healthy donors,
adjusted to 1×107 neutrophils/mL in Krebs-Ringer buffer
with 10 mM glucose, and aliquots were incubated for up to
4 days aerobically and anaerobically. All experiments were
performed at least in triplicate.
2.5. Bacterial lactate production
Bacterial identification was performed using the Vitek®
biochemical identification system (Senior Model 120, bioMér-
ieux) for facultative anaerobes and the RapID Ana II® (Remel,
Lenexa, KS, U.S.A.) identification system and the ERIC®
software (Electronic RapID Compendium version 1.0, Remel)
for obligate anaerobes. The bacteria were quantified in triplicate
by plating tenfold serial dilutions on Columbia agar. For in vitro
lactate determination, the facultative anaerobes P. aeruginosa
PAO1 [25], S. aureus SA113 [26], and B. cenocepacia J 2315
[27] were used. Bacteria were grown in Tryptone Soy Broth
(Oxoid, Basingstoke, England). This growth medium contains
glucose, all amino acids, and nitrate thus resembling the
composition of CF sputum. Bacteria were grown aerobically for
24 h, starting concentration was 1×107 cfu/mL. In addition, the
two obligate anaerobic patient strains S. saccharolyticus (syn:
Micrococcus saccharolyticus) and Veillonella spp. were grown
in an anaerobic bench (MAKS/MG, Meintrup, Lähden-Holte,
Germany) for 4 days.
2.6. Statistics
Results are given as means±standard deviation (Microsoft
Excel 2002, Redmond, WA, U.S.A.). Correlations (Pearson
correlation coefficient r) and significances (Student's t-test p)
were calculated using the Statistical Package for Social Sciences
(Version 15, SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Lactate in CF patients with respiratory exacerbations
To investigate if lactate changes during antibacterial therapy,
we measured sputum lactate concentrations at the time ofexacerbation and after treatment. The mean lactate concentra-
tions decreased significantly (p=0.0043) from 3.4±2.3 mmol/L
to 1.4 ± 1.4 mmol/L (Fig. 1A). The mean FVC values
simultaneously increased from 60.3±21.0 to 70.7±19.9%
(p=0.13, Fig. 1B). FEV1 values increased from 41.7±18.4 to
52.0±19.8% (p=0.11, data not shown). In the majority of the
patients (n=16, 88.9%), FVC values increased after treatment
(p=0.039), whereas the lactate concentrations decreased. In the
remaining two patients, antibiotic treatment was unsuccessfull,
reflected by decreasing FVC and increasing lactate. Obviously,
sputum lactate concentrations in exacerbated CF patients reflect
lung function changes before and after treatment.3.2. Lactate in CF patients without exacerbations
We measured lactate in sputum of 25 CF patients without
exacerbations. The mean lactate concentration was
3.0±3.1 mmol/L (range 0.2 to 14.1 mmol/L) (Fig. 2). Lactate
was detectable in sputa from all of the 25 patients. High lactate
values correlated with low FEV1 values (r=−0.446, p=0.043),
whereas for FVC, correlation coefficients were lower (not
significant, data not shown). Conversely this means: low lactate
concentrations in sputum correlate with high lung function
values. When lactate concentration and MPO activity in sputum
samples of a subgroup of 21 CF patients were correlated, the
correlation coefficient came to r=0.445.
Fig. 2. In sputum of stable CF patients (n=25), lactate and lung function
correlate negatively (r=−0.446).
Fig. 3. Human neutrophils [5×106 cells/mL] incubated aerobically (+O2) or
anaerobically (−O2) for 4 h, produced more lactate during anaerobiosis if freeze-
cracked (#) or not.
Fig. 4. Lactate production by human neutrophils [1×107 cells/mL] grown
aerobically (■) and anaerobically (□) for up to 4 days.
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In a small group of seven CF patients, lactate concentrations
and neutrophil numbers were determined simultaneously in
BAL samples before and after i.v. therapy. Neutrophils
decreased from 13.4±17.5×105 cells/mL before treatment to
4.6±4.8×105 cells/mL after i.v. therapy (p=0.23). Lactate was
detectable in merely two out of seven BAL samples in small
amounts before treatment (0.4±0.6 mmol/L), and was below
the detection limit after treatment in all but one patients.
Neutrophil numbers showed a high correlation with lactate
concentrations in BAL (r=0.8591, p=0.023). However, the
lactate values are much too low for a reliable statement. Thus,
BAL samples because of the high dilution are not feasible for
lactate determination.
3.4. Control patients
To investigate whether the presence of lactate in sputum is
specific for CF patients, we measured lactate in sputum samples
from seven patients with COPD without exacerbation. Lactate
was detected in all sputa with a mean value of 1.6±0.8 mmol/L
lactate (range 0.4 to 2.6 mmol/L). In another three patients with
chronic lung inflammation and without sputum production, the
lactate values in BAL again were below the limit of detection.
Thus, lactate in sputum is not unique for CF patients, but can
also be found in somewhat lower concentrations in respiratory
secretions from patients with COPD and sputum production.
However, the contribution of bacteria to the lactate concentra-
tion in COPD sputum cannot be excluded.
3.5. Neutrophil lactate production
When human neutrophils [5×106 cells/mL] were incubated
aerobically for 4 h, they produced 1.6±1.0 mmol/L lactate
(Fig. 3). This amount did not increase significantly following
storage at −20 °C to crack the cell membranes (2.1±1.2 mmol/
L). Aliquots incubated anaerobically produced nearly three
times more lactate (p=0.044) without (4.8±3.1 mmol/L) or
with (4.9±3.1 mmol/L) additional freeze cracking. Thus, lactate
does not remain intracellularly, and short-term anaerobic
exposure leads to increased neutrophil lactate production.
When the neutrophil [1×107 cells/mL] incubation time was
further increased to 4 days, the lactate concentration increasedslower, and the difference between the aerobic and anaerobic
experiments was less pronounced (Fig. 4). However, there was
still a small amount of lactate produced even on day 4,
suggesting lactate accumulation.
3.6. Bacterial lactate production in sputum and in vitro
The mean lactate concentration in our 25 sputum samples was
3.0±3.1 mmol/L which did not differ significantly from lactate
concentrations in the 14 sputum samples with P. aeruginosa
(3.3±3.7 mmol/L) and in the 10 samples harbouring S. aureus
(2.8±2.3 mmol/L). The sputum with B. cenocepacia contained
1.9 mmol/L. Sputum colony counts measured aerobically
ranged from 9.2 × 104 to 1.5 × 109 cfu/mL, mean ± SD
8.3×107 ±2.9×108 cfu/mL. Colony counts in the samples
contaminated with P. aeruginosa (1.3×108±3.9×108 cfu/mL)
were similar to those in the samples with S. aureus
(1.2×107±1.2×107 cfu/mL, p=0.26). The sputum with B.
cenocepacia contained 7.7×107 cfu/mL. When colony forming
units in all samples were correlated to the respective lactate
values in the same sputum samples, no correlation was found
(r=0.155). Since CF sputum samples contain similar amounts of
lactate independent from their bacterial colonization, this
colonization does not appear to represent the dominant source
for the lactate concentration in sputum.
Exemplarily, the lactate production from three frequently
occurring facultative anaerobes P. aeruginosa, S. aureus, and B.
cenocepacia, and from two obligate anaerobes S. saccharoly-
ticus and Veillonella spp. was investigated (Table 1). Merely S.
aureus produced after 24 h of aerobic growth 1.9 mmol/L
lactate. All other bacteria did not produce any lactate at all. This
Table 1
Lactate production by facultative and obligate anaerobic bacteria.
PA SA BC SS V
+O2 for 24 h b0.2 1.9 b0.2 – –
−O2 for 4 days b0.2 b0.2 b0.2 b0.2 b0.2
Pseudomonas aeruginosa (PA), Staphylococcus aureus (SA), Burkholderia
cenocepacia (BC), Staphylococcus saccharolyticus (SS), or Veillonella spp. (V)
bacteria [1×107 cfu/mL] were incubated aerobically (+O2) for 24 h or
anaerobically (−O2) for 4 days. Total lactate was determined gaschromato-
graphically. Values are given in mmol/L.
Fig. 5. High correlation (r=0.8386) between lactate concentration and lactate
dehydrogenase (LDH) activity in CF sputum samples (n=29).
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solutions of the facultative anaerobes with 10 mmol/L lactate
showed no lactate consumption (data not shown). These results
correspond with the lactate concentrations in our sputum
samples.
3.7. Lactate characteristics
In 29CF sputum samples, lactate and LDHwere determined in
parallel. Activities for LDH ranged from 22 to 345 (mean±SD:
135±89) μmol/L s. Rising LDH activities correlated (r=0.8386,
Fig. 5) with increasing lactate concentrations. Thus, both lactate
concentrations and LDH activities are associated with neutrophil
numbers in vivo.
The stability of lactate and LDH was determined for 16
sputum supernatants after 30 days of storage at −51 °C or 6 °C.
After 30 days at −51 °C, the lactate concentration was
103.7±7.8% of the initial values. The lactate concentration
was also maintained at 102.1±6.8% after storage for 30 days at
6 °C. Values for LDH remained stable when frozen at −51 °C
(93.5±33.4% after 30 days) but decreased considerably when
stored at 6 °C (47.0±29.3%). When four sputum samples
without centrifugation were stored in a fridge, the lactate
concentrations were 4.7±2.0 before and 4.5±2.3 after storage.
Thus, lactate – compared to LDH – is stable even after one
month of storage in the fridge.
In two patients, lactate concentrations in BAL were
determined from sequential lavage aliquots with 10 mL NaCl
in the same lung lobe. Lactate decreased from 8.0 to 3.7, 1.6, 0.5
and 0.5 mmol/L in the first patient and from 9.5 to 2.8, 1.2, 0.4
and 0.7 mmol/L in the second patient. Thus, the sequential
dilution of airway secretions with repeated lavage in a given
location showed a progressive decline in lactate levels.
4. Discussion
In this paper we show for the first time that lactate
concentrations in CF sputum decrease following successful
treatment of exacerbations while lung function values increase
(Fig. 1A, B). Additionally we demonstrate that lactate
concentrations in sputa from CF patients without exacerbations
correlate inversely with spirometric measures of lung function
(Fig. 2). The finding that lung function values increase
following antimicrobial treatment is well-known, lung function
measurements represent the gold standard for therapy control
[1,20,21,28]. However, the concomitant decrease of the sputumlactate concentrations provides additional information on the
progress of inflammation during exacerbations. Also in stable
CF patients, both high lactate concentrations and low lung
function values may well be interpreted as concomitant effects
of inflammation. The high mean value for lactate in our stable
patients (and the high standard deviation) is influenced by one
patient with the exorbitant lactate concentration of 14.1 mmol/L
despite a stable clinical status. However, for therapy control the
progression of the sputum lactate concentration is crucial, and
not the absolute values. Even in the few patients without lung
function response to antibiotic treatment, the lactate concentra-
tions remain high indicating ongoing inflammation. The lactate
concentrations in the sputum samples appear to be independent
of CF specific pathogens.
The investigations in our control patients yielded comparable
results: in the BAL samples from non-CF patients with lung
inflammation but without sputum production, lactate was below
the detection limit. In contrast, in COPD patients [29], lactate
was detectable (although in lower values) in sputum from every
single patient. Thus, lactate production is not specific for CF but
it can also be found in the neutrophil-dominated chronic lung
disease COPD [29].
We speculate that the increase in lung function and the
associated decrease in lactate concentrations occurs as a result
of a reduction in bacterial numbers combined with a reduction
in neutrophil-mediated inflammation (Fig. 6). Antibiotic
treatment against P. aeruginosa has previously been correlated
with decreased bacterial numbers [30–32]. Similarly, successful
therapy for respiratory exacerbations has been shown to
decrease inflammation [1,20,21]. A reduction in bacterial-
derived chemotactic stimuli for neutrophils may, in part,
account for reduced neutrophil numbers in response to
antibacterial therapy [28,32].
Our in vitro studies indicate that increased lactate concentra-
tions in CF sputa are likely derived from neutrophils which
secrete the lactate completely (Fig. 3). Lactate concentrations in
the sputum samples appear to be independent of bacterial
colonization. Augmented amounts of lactate are produced when
neutrophils utilize anaerobic metabolic pathways (Fig. 3). Such
anaerobic conditions partially prevail in the sputum inside the
CF lung, and neutrophils can easily survive and perform on
such terms [12,33–35]. Neutrophils in high concentrations
consume oxygen resulting in anaerobic conditions [35]. This
Fig. 6. In sputum with an oxygen gradient (dark green: +O2, light green: −O2)
inside the airways of CF patients with stable chronic lung infection and
inflammation (A), neutrophils and bacterial microcolonies exist at equilibrium.
Planctonic bacteria in the +O2 layer are killed effectively. Sputum lactate
concentrations (L) and forced expiratory volume in 1 s (FEV1) are in steady-
state. During exacerbations (B), the balance is destabilized, additional
neutrophils arise, extensive sputum production occurs, FEV1 decreases, and
lactate concentration increases. When antibiotic or antiinflammatory treatment is
successful (C), neutrophils phagocytose the remaining bacteria, the surplus
sputum may be coughed out, and FEV1 and lactate concentrations begin to
normalize. At the end of an exacerbation (D), the status quo ante is reached
again, and lactate as well as FEV1 return to initial values.
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tions in vitro for up to 4 days, the difference between aerobic
and anaerobic lactate production was not visible any more
(Fig. 4). Furthermore no decrease in lactate production was
observed. Rather accumulation of lactate occurred (Fig. 4)
suggesting that lactate is not decomposed by neutrophils, but
rather persists as a stable, non-volatile substance under in vitro
as well as in vivo conditions.
Lactate concentration in blood samples of CF patients
(1.3±0.4 mmol/L [36]) is within the range for normal values in
healthy persons (0.55 to 2.2 mmol/L) [36]. The blood lactate
concentrations for CF patients were considerably lower than
that for sputum (3.0±3.1 mmol/L) which suggests that a
significant diffusion of lactate into sputum does not occur in
vivo. These observations additionally implicate neutrophils as
the predominant source of lactate in CF sputa.
LDH likewise is produced by neutrophils, and LDH
activities show a high correlation with lactate in sputum
(Fig. 5). However, LDH is unstable compared to lactate, and
measurements are influenced by temperature and may change
with time [37]. Our freezing experiments showed that LDH
activities dropped to 47.0±29.3% after 30 days, whereas lactate
determinations remained stable for at least one month.
Furthermore, P. aeruginosa exhibits three genes encoding for
LDH, which in turn may affect neutrophil LDH activity
determinations [25]. Therefore, we suggest that lactate
determinations in CF sputa are more reliable than LDH activity
measurements.
The correlation between lactate concentration and MPO
activity in CF sputum supports the notion that both compounds
concertedly are derived from neutrophils. However, the low
correlation coefficient may be influenced by the fact that MPO
activity underlies proteolytic degradation.
Lactate concentrations were considerably lower in BAL
specimens from CF patients with respiratory exacerbations as
compared to those in sputum. Despite dilution (approximately
100-fold), lactate was still detectable in some pre-treatment
BAL specimens and correlated with neutrophil concentrations.
However, after treatment the concentrations in all but one CF
patient (who had a poor response to antibiotic therapy) were
below the lower limit of detection. Therefore BAL samples are
not feasible for lactate determination.
P. aeruginosa, B. cenocepacia, S. saccharolyticus or
Veillonella spp. were not observed to produce or consume
lactate in substantial amounts (Table 1). Merely S. aureus
produced 1.9 mmol/L lactate under aerobic growth conditions
that do not prevail in large parts of the CF sputum plugs.
Anaerobically also S. aureus does not produce lactate at all
(Table 1). In addition, the lactate concentrations in sputa
colonized with S. aureus do not differ from those colonized with
other bacteria suggesting a neglectable influence of bacterial
lactate production on the overall sputum concentrations.
Although P. aeruginosa anaerobically can produce lactate
from pyruvate [22], for P. aeruginosa the most beneficial
anaerobic metabolic pathway is to metabolize nitrate, followed
by arginine and pyruvate [22]. Lactate production by pyruvate
fermentation only occurs, if P. aeruginosa cannot use aerobic
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nitrate and all amino acids are present in the CF sputum in high
amounts, pyruvate fermentation is unlikely to occur. However,
a contribution of bacteria to the total lactate concentration in
sputum cannot be excluded.
Taken together, our findings suggest that lactate represents a
non-volatile neutrophil metabolite that remains stable when
specimens are frozen. The determination of lactate concentra-
tion is reproducible and can be performed using routine assay
methods. Lactate was detected in sputa from all of our patients
with CF, and changes in sputum lactate concentration may be
useful to monitor the success of antibaterial and/or anti-
inflammatory therapies. However, young patients who lack
sputum production cannot be assessed via lactate measurement
in expectorated sputum. Lactate determination may also be of
use to monitor neutrophil-dominated airway inflammation in
patients with other chronic lung diseases associated with
sputum production such as COPD or non-CF bronchiectasis.
Lactate measurement in sputum is non-invasive and could be
performed frequently to monitor the effect of therapy. If
treatment of a respiratory exacerbation is unsuccessful (as
reflected by lack of improvement or worsening in lung function
parameters) lactate values are likely to remain increased.
We conclude that lactate concentrations in sputum reflect
neutrophil influx and inflammation in the lower respiratory tract
of CF patients with respiratory exacerbations. Elevated lactate
levels reflect predominantly anaerobic metabolism by neutrophils
due to relative hypoxic conditions in CF respiratory secretions,
and lactate levels decline with successful therapy. Lactate
concentrations in sputum may provide a useful biomarker of
infection and inflammation in the CF lower respiratory tract and
should be evaluated in prospective clinical trials.
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